comparemela.com

Latest Breaking News On - Astrazeneca daiichi sankyo enhertu - Page 1 : comparemela.com

AACR: Biotechs emerge frostbitten from 'nuclear winter'

AACR: Biotechs emerge frostbitten from 'nuclear winter'
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

United-states
San-diego
California
American
Steve-bellon
Ahmed-hamdy
Raquel-izumi
Astrazeneca-daiichi-sankyo-enhertu
Adrian-gottschalk
Brian-fiske
Eli-lilly-loxo
American-association-for-cancer-research

Gilead's breast cancer drug secures U.S. FDA approval for expanded use

(Reuters) -Gilead Sciences Inc said on Friday the U.S. Food and Drug Administration had greenlighted expanded use of Trodelvy to treat the most common.

United-states
Bengaluru
Karnataka
India
Bhanvi-satija
Raghav-mahobe
Shinjini-ganguli
Astrazeneca-daiichi-sankyo-enhertu
Drug-administration
Gilead-sciences-inc
Reuters
Astrazeneca-daiichi-sankyo

Bumper December meeting sees CHMP recommend 15 new medicines

Bumper December meeting sees CHMP recommend 15 new medicines 14th December 2020 The European Medicines Agency’s (EMA) committee for Medicinal Products for Human Use (CHMP) recommended 15 new medicines for approval in its final meeting of the year. First to score a recommendation was AstraZeneca/Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for the treatment of metastatic HER2-positive breast cancer, following an accelerated review of the anti-HER2 therapy. The CHMP also recommended Dynavax’s Heplisav (hepatitis B surface antigen) for active immunisation against hepatitis B virus infection and ViiV Healthcare’s Rukobia (fostemsavir) for the treatment of multidrug resistant HIV-1 infection. Up next, the CHMP adopted a positive opinion for Bristol Myers Squibb’s Inrebic (fedratinib) for the treatment of primary myelofibrosis and myelofibrosis secondary to polycythaemia vera, as well as essential thrombocythaemia.

Mylan-kixelle
Dynavax-heplisav
Bristol-myers-squibb-inrebic
Astrazeneca-daiichi-sankyo-enhertu
Lenalidomide-krka
Eli-lilly-retsevmo
Seagen-tukysa
Astrazeneca-lumoxiti
European-medicines-agency
Medicinal-products
Human-use
Daiichi-sankyo

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.